The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
 
Vivek Bhadri
Consulting or Advisory Role - Deciphera
 
Hans Gelderblom
Research Funding - Abbisko Therapeutics (Inst); AmmaxBio (Inst); Blueprint Medicines (Inst); Deciphera (Inst); InhibRx (Inst); Ipsen (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Abbisko Therapeutics (Inst); Merck (Inst)
 
Silvia Stacchiotti
Honoraria - Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar; Servier
Consulting or Advisory Role - Agenus; Bayer; Boehringer Ingelheim; Daiichi Sankyo; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; NEC OncoImmunity AS; Pharmaessentia; Regeneron; SERVIER
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Sebastian Bauer
Honoraria - Deciphera; Pharmamar
Consulting or Advisory Role - Adcendo; Blueprint Medicines; Boehringer Ingelheim; Deciphera; IDRX
Research Funding - IDRX (Inst); von Pfeffel (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for a drug to treat a sarcoma subtype (Inst)
 
Andrew Wagner
Honoraria - AADi; Cogent Biosciences
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono/Merck; InhibRx; Pharmaessentia; SERVIER
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Rain Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
 
Michiel van de Sande
Honoraria - Daiichi Sankyo Europe GmbH; Dicephera Pharmaceuticals, Inc.; Merck KGaA
Research Funding - Implatcast GMbH (Inst)
 
Nicholas Bernthal
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Onkos Surgical; Zimmer Biomet
Research Funding - Daiichi Sankyo; Deciphera; Onkos Surgical; Zimmer Biomet
 
Antonio López Pousa
No Relationships to Disclose
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Merck; Neoleukin Therapeutics; Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Mahbubl Ahmed
No Relationships to Disclose
 
Axel Le Cesne
Honoraria - Deciphera
 
Christopher Tait
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Amanda Saunders
Employment - Deciphera
Stock and Other Ownership Interests - AstraZeneca (I)
 
Nicholas Zeringo
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
Travel, Accommodations, Expenses - Deciphera
 
Brooke Harrow
Employment - Deciphera; Lilly (I)
Stock and Other Ownership Interests - Deciphera; Vertex
 
Maitreyi Sharma
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Matthew Sherman
Employment - Deciphera
Leadership - Deciphera
Stock and Other Ownership Interests - Deciphera
Patents, Royalties, Other Intellectual Property - Deciphera
Travel, Accommodations, Expenses - Deciphera
Other Relationship - Pieris Pharmaceuticals
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Avacta Life Sciences; Bayer; Boehringer Ingelheim; C4 Therapeutics; Curadev; Daiichi Sankyo; Deciphera; Ikena Oncology; IMGT; inhibrx; Ipsen; PharmaEssential; Ratio; Servier; Sonata
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
on behalf of the MOTION Investigators
No Relationships to Disclose